Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression

Movement Disorders

Volumn 29, Issue 2, 2014, Pages 207-213

  Baumann, Christian R ^a   Held, Ulrike ^b   Valko, Philipp O ^a   Wienecke, Miriam ^a   Waldvogel, Daniel ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Akinesia; Parkinson's disease; Prognosis; Tremor

Indexed keywords

AKINESIA; PARKINSON'S DISEASE; PROGNOSIS; TREMOR;

AGED; ANTIPARKINSON AGENTS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FUNCTIONAL LATERALITY; HALLUCINATIONS; HUMAN BODY; HUMANS; HYPOKINESIA; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 84894231296     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25650     Document Type: Article

References (26)

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
2. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002;59:1724-1728.
3. Post B, Merkus MP, de Haan RJ, Speelman JD; CARPA Study Group. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22:1839-1851.
4. Marras C, McDermott MP, Marek K, et al; Parkinson Study Group DATATOP and PRECEPT Investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 2011;26:608-613.
5. Katzen HL, Levin BE, Weiner W. Side and type of motor symptom influence cognition in Parkinson's disease. Mov Disord 2006;21:1947-1953.
6. Tomer R, Levin BE, Weiner WJ. Side of onset of motor symptoms influences cognition in Parkinson's disease. Ann Neurol 1993;34:579-584.
7. Viitanen M, Mortimer JA, Webster DD. Association between presenting motor symptoms and the risk of cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:1203-1207.
8. Stavitsky K, McNamara P, Durso R, Harris E, Auerbach S, Cronin-Golomb A. Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neurol 2008;21:143-149.
9. Fahn S, Elton RL and the members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Liebermann A, editors. Recent Development in Parkinson's Disease. Florham Park, NJ: MacMillan Health Care Information; 1987:153-163.
10. Schmidgen H, Hoell T, Regard M, Landis T, Rudolf KH, Berzewski H, Brock M. The "Neuropsychological Screening Test (NST)": initial validation and reliability studies. Zentralbl Neurochir 1994;55:185-192.
11. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
12. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. Darian, IL: American Academy of Sleep Medicine; 2005.
13. Bloch KE, Schoch OD, Zhang JN, Russi EW. German version of the Epworth sleepiness scale. Respiration 1999;66:440-447.
14. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102.
15. Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR. Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 2010;17:1428-1436.
16. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
17. German Society of Neurology. Guidelines of the German Society of Neurology. Available at: www.dgn.org.
18. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
19. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211-1216.
20. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 2009;256:256-263.
21. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351-6356.
22. van der Hoorn A, Burger H, Leenders KL, de Jong BM. Handedness correlates with the dominant parkinson side: a systematic review and meta-analysis. Mov Disord 2012;27:206-210.
23. Giardino L. Right-left asymmetry of D1- and D2-receptor density is lost in the basal ganglia of old rats. Brain Res 1996;720:235-238.
24. Doron O, Goelman G. Evidence for asymmetric intra substantia nigra functional connectivity application to basal ganglia processing. Neuroimage 2010;49:2940-2946.
25. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
26. Iranzo A. The importance of sleep medicine consultation for diagnosis of REM sleep behavior disorder in most patients with Parkinson's disease. Sleep Med 2002;3:537-538.